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Abstract
Rationale Most widely used antidepressant drugs affect the
serotonergic and noradrenergic pathways. However, there
are currently no neurobiological criteria for selecting
between these targets and predicting the treatment response
in individual depressed patients.
Objectives The current study is aimed at differentiating
brain regions known to be pathophysiologically and
functionally involved in depression-related emotion pro-
cessing with respect to their susceptibility to serotonergic
and noradrenergic modulation.
Methods In a single-blind pseudo-randomized crossover
study, 16 healthy subjects (out of 21 enrolled) were
included in analysis after ingesting a single dose of
citalopram (a selective serotonin-reuptake inhibitor,
40 mg), reboxetine (a selective noradrenaline-reuptake
inhibitor, 8 mg), or placebo at three time points prior to
functional magnetic resonance imaging (fMRI). During
fMRI, subjects anticipated and subsequently viewed emo-
tional pictures. Effects of serotonergic and noradrenergic
modulation versus placebo on brain activity during the
perception of negative pictures were analyzed with a
repeated measures ANOVA in the whole brain and in
specific regions of interest relevant to depression.
Results Noradrenergic modulation by reboxetine increased
brain activity in the thalamus, right dorsolateral prefrontal
cortex and occipital regions during the perception of
negative emotional stimuli. Citalopram primarily affected
the ventrolateral prefrontal cortical regions.
Conclusion The brain regions involved in the processing of
negative emotional stimuli were differentially modulated by
selective noradrenergic and serotonergic drugs: thalamic
activity was increased by reboxetine, whereas citalopram
primarily affected ventrolateral prefrontal regions. Thus,
dysfunction in these regions, which could be identified in
depressed patients, may predict treatment responses to
either noradrenergic or serotonergic antidepressants.
Keywords Citalopram . Reboxetine . Depression . Emotion
processing . Functional neuroimaging
Introduction
Selecting the optimal antidepressant drug to achieve a good
clinical response in an individual depressed patient remains
a challenge in psychiatric praxis. Currently, there are no
validated neurobiological treatment-selection criteria that
dictate which type of antidepressant to use (Mayberg 2003;
Bruder et al. 2008), and many patients exhibit considerable
treatment resistance in depression. In the future, it may be
possible to obtain brain activation patterns in individual
patients using functional neuroimaging to provide a basis
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for selecting the most efficient drug more quickly and
reliably.
An important step towards such a strategy would be
identifying which brain regions that are altered in depres-
sion and involved in emotion processing-related activity are
susceptible to antidepressant agents. With this knowledge,
one could identify regions with dysfunctional or pathophy-
siologically relevant information processing in a single
depressed patient and then prescribe an antidepressant
compound that can modify the information processing to
promote mental health.
Functional neuroimaging studies in depression have
repeatedly shown increased brain activity in response to
particularly emotionally negative stimuli (pictures and
faces) in a network of regions comprising the amygdala,
ventral or pallidostriatum, thalamus, hippocampus, ventral
and dorsolateral prefrontal cortex (VLPFC, DLPFC),
insula, ventral and subgenual regions of the anterior
cingulate cortex, and occipital visual regions (Elliott et al.
2002; Kumari et al. 2003; Phillips et al. 2003; Herwig et al.
2010).
During the course of treatment, brain activity can change
or “normalize” in these regions (Sheline et al. 2001;
Davidson et al. 2003; Fu et al. 2004; Little et al. 2005;
Keedwell et al. 2009; Frodl et al. 2011; meta-analysis—
Fitzgerald et al. 2008). Thus, applying clinically effective
treatments can influence brain activity in previously
“dysfunctional” regions, corresponding to the clinical
improvement.
Currently available antidepressant drugs primarily act on
monoaminergic pathways, especially the serotonergic and/
or the noradrenergic systems (Schloss and Henn 2004). In
the current study, we used functional magnetic resonance
imaging (fMRI) to examine the responses of healthy
subjects exposed to emotionally relevant stimuli after an
acute serotonergic and noradrenergic challenge in a single-
blind placebo-controlled crossover design. Single doses of
either citalopram, the most selective serotonin-reuptake
inhibitor (Hyttel 1982), or reboxetine, the most selective
noradrenaline reuptake inhibitor (Tatsumi et al. 1997), were
expected to enhance serotonergic or noradrenergic trans-
mission in those regions (1) activated by the task and (2)
modulated by serotonergic or noradrenergic neurons.
During the task, subjects were presented negative, positive,
and neutral emotional pictures after a cued anticipatory
period. An analysis of the anticipation period has been
reported previously (Brühl et al. 2010). Here, we focused
on the perception of negative pictures because this type of
stimuli has revealed clear differences in brain activity in
depressed patients (Sheline et al. 2001; Elliott et al. 2002;
Kumari et al. 2003; Fu et al. 2004; Fitzgerald et al. 2008).
We hypothesized that the two antidepressants tested
would exhibit distinct modulating influences on emotion
processing in the aforementioned network of brain regions.
The resulting distinguishable patterns of modulated brain
regions may serve as future target regions for treatment
prediction purposes. We analyzed pharmacological effects
in the whole brain and in anatomically defined regions of
interest (ROIs) in the amygdala, anterior insula, thalamus,
DLPFC, and anterior cingulate cortex.
Materials and methods
Subjects
Twenty-one healthy subjects (mean age 28.1 years, right-
handed, 14 females) were recruited. After receiving a
complete description of the study, they gave written
informed consent. The study was approved by the local
ethics committee. Subjects did not have any current or
previous neurological or psychiatric illnesses, as assessed
by a semi-structured interview. Additional exclusion criteria
included pregnancy; current medications (except for oral
contraceptives); excessive consumption of alcohol, ciga-
rettes, and caffeine; and contraindications against MRI
examination. Prior to inclusion, subjects completed a self-
rating assessment of depression and anxiety (for demo-
graphic and psychometric data, see Online Resource 1).
Each of the subjects was intended to undergo three scans.
However, a total of five subjects were excluded from
analysis due to pathological findings (one subject), with-
drawal from the study (one subject), or excessive head
movements throughout scanning (three subjects). One scan
from each of three of the remaining 16 subjects (mean age
28.4 years, 12 females) could not be completed due to
technical problems during scanning. In total, we obtained
45 datasets that were included in the analysis (outlined
graphically in Online Resource 2).
Drug treatment
Prior to each scan, each subject received a typical
therapeutic dose of citalopram (CIT, 40 mg), reboxetine
(RBX, 8 mg), or placebo (PLC, lactose) in a pseudo-
randomized order. The tablets were dispensed in a sealed,
neutral wrapping such that subjects were unaware of which
drug they were taking. Subjects were instructed to take the
respective tablets about 2.5 h prior to scanning because
peak concentrations of both drugs are observed 2–4 h after
oral application (Fleishaker 2000; Joubert et al. 2000). At
this therapeutic dose of citalopram, serotonin-transporter
occupancy exceeds 80% (Meyer et al. 2004). Similar data
for occupancy of the noradrenaline transporter after
reboxetine treatment are currently unavailable. A minimal
washout period of 1 week was implemented between each
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scan, corresponding to at least five half-lives of each
substance. The order of drug administration across sessions
was counterbalanced by pseudo-randomization. Before and
after scanning, subjects were asked about any perceived
side effects and their experiences with the experiment in the
scanner.
Experimental design
During fMRI scanning, participants performed a task
(programmed with PresentationTM, Neurobehavioral Sys-
tems, USA) comprising 56 trials with expectation and
perception of emotional pictures (detailed description in
Herwig et al. 2007). Within each trial, a cue was given
(duration 1,000 ms), depicting either a “smiling” (“posi-
tive”) “∪”, “non-smiling” (“negative”) “∩”, or “neutral”
symbol “−” that indicated the emotional valence of the
upcoming picture, or an “unknown” symbol “|”, after which
either a pleasant or an unpleasant picture appeared
randomly. Thereafter, the respective emotional picture was
presented. Notably, the term “unknown” as used here refers
to the fact that the emotional valence of the upcoming
picture was unknown because it was cued ambiguously.
The cues were 1/20th the height of the screen, and the
pictures filled the screen. This cueing design was chosen,
among other reasons, to reduce anticipatory and preparatory
activation caused by the emotional pictures. The “unknown”
condition was intended only for the anticipatory phase; the
respective pictures were not analyzed.
The anticipation period lasted 6,920 ms [fixation point;
cue plus anticipation=4 repetition times of MRI scanning
(TR)]. Subsequently, emotional pictures from the Interna-
tional Affective Picture System (IAPS) were presented for
7,920 ms (4 TR). The following baseline period
(15,840 ms, 8 TR) was of sufficient duration to allow the
blood oxygen level-dependent signal to wear off before the
next trial. Each condition consisted of 14 trials in a
randomized order.
Participants were instructed to expect emotional stimuli
following the cue, to be aware of the indicated emotional
valence, and to look at the upcoming emotional picture.
Before scanning, all participants performed a training
session, during which they were presented a shorter
version of the task with similar pictures. To avoid
memory effects, the pictures from the training session
did not appear during the main task. Thus, the
participants were familiar with the timing, cues, and
range of content of the pictures. Three sets of 56 stimuli
each were randomly assigned to the sessions. Within
and between these sets, stimuli were matched with
respect to valence, complexity, and content (IAPS
picture rating; for detailed information, see Brühl et al.
2010).
Immediately after each scan, subjects rated the emotional
valence of the presented pictures (presented again as
printouts) on a nine-point rating scale (1—very negative/
unpleasant, 9—very positive/pleasant).
FMRI acquisition
Imaging was performed using a 3.0-T GE Signa HD
Scanner (GE Medical Systems, USA, eight-channel head
coil). Echo-planar imaging (EPI) was performed for fMRI
[repetition time (TR)/echo time (TE) 1,980 ms/32 ms, 22
sequential axial slices, whole brain, slice thickness/gap
4.5 mm/0.5 mm, voxel size 3.4 mm×3.4 mm×5 mm,
matrix 64 pixels×64 pixels, field of view 220 mm].
Altogether, 908 volumes within one run were obtained per
session. High-resolution 3-D T1-weighted anatomical vol-
umes were acquired (voxel size 1 mm×1 mm×1 mm, axial
orientation) for co-registration with the functional data.
Furthermore, T2-weighted images in parallel to the EPI
sequence were acquired to exclude possible T2-sensitive
abnormalities. Stimuli were presented via digital goggles
(Resonance Technologies, USA).
fMRI data analysis and statistics
fMRI data were analyzed using BrainVoyager QX 2.07
(Brain Innovation, The Netherlands). Preprocessing
included motion correction, slice scan time correction,
high frequency temporal filtering, and removal of linear
trends. Functional and 3-D structural measurements
were co-registered and structural and functional data
sets were transformed into Talairach space, resulting in
a voxel size of 3 mm×3 mm×3 mm. Finally, the
datasets were spatially smoothed with an 8-mm full-
width half-maximum Gaussian kernel for subsequent
group analysis.
The design matrix was built for analyzing intra-
subject comparisons between the three treatment con-
ditions (CIT, RBX, and PLC). The functional data were
convoluted with a two-parameter gamma hemodynamic
response function (HRF). There are no direct methodo-
logical studies addressing the potential effects of
citalopram and reboxetine on HRF. Two studies, how-
ever, mentioned no changes of the hemodynamic
reaction by reboxetine in a visual (Miskowiak et al.
2007) and citalopram in a motor task (Wingen et al.
2008).
In the first step of our analysis, separate beta maps for
each subject were computed for the single contrast
“negative”>“neutral” (ng>nt) and “positive”>“neutral”
(ps>nt) for each of the treatment conditions. These maps
were then combined in a repeated measures ANOVA with
the within-subjects factors “treatment” (CIT, RBX, PLC)
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and “condition” (ng>nt, ps>nt). For results of the compar-
ison between the two active substances (RBX>CIT), see
the Online Resource 4. The statistical significance level was
set at p <0.0005, which corresponds to an FDR-corrected
level of at least q <0.05. We used a cluster threshold of five
voxels of 3 mm×3 mm×3 mm (135 mm3).
Additionally, we analyzed the influence of citalopram and
reboxetine in anatomically defined ROIs by positioning cubic
ROIs in the bilateral amygdala, bilateral thalamus, and bilateral
rostral and ventral anterior cingulate cortex (edge length
10 mm, resulting volume 1,000 mm3) as well as the bilateral
DLPFC and the bilateral anterior insula (edge length 15 mm,
resulting volume 3,375 mm3). For each ROI, the mean effect
sizes were computed based on all voxels included in that
particular ROI. We compared mean beta weights using a
repeated measures ANOVA and calculated effect sizes
(Cohen’s d). Anatomical regions were identified according
to the Talairach system. The results of the anticipation period
have been published previously (Brühl et al. 2010).
Results
Behavioral analysis
Single doses of citalopram and reboxetine had no influence
on ratings of the emotional valence of the pictures
compared to placebo (see Online Resource 3).
Noradrenergic modulation compared to placebo
Enhanced noradrenergic neurotransmission by reboxetine
increased brain activity associated with perceiving negative
versus neutral pictures subcortically in the bilateral caudate
and the dorsomedial thalamus (Fig. 1a–c), including the
pulvinar. Cortically, reboxetine influenced the right superior
frontal gyrus, bilateral posterior cingulate and cuneus, and
bilateral temporal and occipital regions (Table 1, Fig. 1d, e).
There were no significant effects of noradrenergic modula-
tion on the brain activity during the perception of positive
versus neutral pictures.
Serotonergic modulation compared to placebo
Pre-treatment with citalopram caused less of a decrease in
brain activity than placebo in bilateral basal frontal regions
(VLPFC, Fig. 2) and increased brain activity in the right
middle temporal and middle occipital gyrus (Table 1) during
the perception of negative versus neutral pictures. There
were no regions with decreased activity due to citalopram.
Serotonergic modulation had no effects on brain
activity associated with perceiving positive versus neutral
pictures.
Noradrenergic modulation compared to serotonergic
modulation
When comparing the effects of noradrenergic and seroto-
nergic modulation directly, the strong influence of rebox-
etine on the processing of negative emotional stimuli
became more noticeable than in comparison with placebo
(see Online Resource 4, Table 4.1). Particularly, the impact
on subcortical brain regions was clearly seen in an extended
subcortical area including amygdalar, thalamic, midbrain,
and striatal regions and ranging from the anterior cingulate
to the fusiform gyrus bilaterally. Furthermore, bilateral
frontal and parietal regions were noradrenergically modu-
lated. During the perception of negative versus neutral
pictures, there were no regions with increased activity due
to serotonergic influences.
During the perception of positive versus neutral pictures,
the effects of noradrenergic versus serotonergic modulation
was weaker (Online Resource 4, Table 4.2) when compared
to the effects during the negative condition. Reboxetine
increased brain activity in the left superior frontal cortex
and in a region extending from the right anterior insula to
the claustrum, whereas citalopram increased activity in a
small region in the left middle temporal gyrus.
Effects of noradrenergic and serotonergic modulation
in selected ROIs during the perception of negative
versus neutral pictures
In the bilateral amygdala and the thalamus, reboxetine
increased brain activity during the perception of negative
versus neutral pictures to a much greater extent than
citalopram (Table 2). Citalopram inhibited brain activity in
the left thalamus, but PLC did not. The anterior insula was
bilaterally modulated by reboxetine but not citalopram. In
the right DLPFC, we found a large effect of reboxetine
compared to placebo and very large effects of reboxetine in
the bilateral DLPFC compared to citalopram, which had no
significant effect in the bilateral DLPFC. In the two regions
of the anterior cingulate cortex (ACC), the only observed
drug effect was a modulating impact of reboxetine in the
right ventral ACC when compared to citalopram.
Discussion
The aim of our study was to identify brain regions that are
specifically modulated by noradrenergic and serotonergic
antidepressants during the processing of negative emotional
stimuli. Compared to serotonergic agents and placebo,
noradrenergic enhancement had the strongest effects in
thalamic and other subcortical areas. In contrast, serotoner-
gic modulation altered brain activity primarily in distinct
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frontal and occipital regions. In the bilateral amygdalar,
thalamic, and anterior insular and dorsolateral prefrontal
regions, when anatomically defined, noradrenergic
enhancement increased brain activity during the processing
of negative pictures. In the cingulate cortex, the rostral part
was not modulated by the influence of either neurotrans-
mitter system, but the ventral region was sensitive to
noradrenergic modulation. During the perception of posi-
tive stimuli, influences of noradrenergic enhancement could
only be detected in the comparison with the serotonergic
modulation in a prefrontal region and in a region extending
from the anterior insula to the claustrum, whereas in the
same comparison citalopram affected one area in the middle
temporal lobe.
The brain regions modulated here during the perception
of negative emotional stimuli are sites of action for
selective reuptake-inhibiting antidepressants (Cipriani et
al. 2009). The behavioral improvements observed after
antidepressant treatment may depend upon adaptive and
neuroplastic changes that occur in regions expressing
neurotransmitter transporters after repeated administration
of antidepressant drugs (Katz et al. 2004; Donnici et al.
2008). The advantage of the current approach over simply
mapping the binding sites of the respective antidepressants,
which has been done previously (e.g., Laruelle et al. 1988;
Varnas et al. 2004; Schou et al. 2005), is that the current
approach provides information about the interaction of
pharmacological and task-induced changes of brain activity
Fig. 1 Modulation of activity in dorsomedial thalamus (a, b, c) and
right medial occipitotemporal gyrus (d, e) by noradrenergic reuptake-
inhibition (RBX) compared to placebo (PLC). In the left panel, a
coronal brain section with the significant clusters (a, d), position
indicated by the y-coordinate. In the middle panel, the respective
averaged event-related time courses of BOLD response (b, e) with the
perception period in the bright field. The box plot on the right (c)
shows the mean beta weights of the conditions reboxetine and placebo
in the thalamic cluster. Intra-subject repeated measures ANOVA (n=
13, p<0.0005, color bars representing t values). Abbreviations: R
right, ng negative, nt neutral
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Fig. 2 Serotonergic modulation
of activation in the right inferior
frontal gyrus/ventrolateral pre-
frontal cortex (VLPFC) by cit-
alopram (CIT) compared to
placebo (PLC). On the left pan-
el, a coronal brain section with
the significant cluster (a), posi-
tion indicated by the y-coordi-
nate. In the right panel, the
respective averaged event-
related time course of BOLD
response (b) with the perception
period in the bright field. Intra-
subject repeated measures
ANOVA (n=15, p<0.0005, col-
or bars representing t values).
Abbreviations: R right, ng neg-
ative, nt neutral
Table 1 Brain regions with increased activity after pre-treatment with citalopram and reboxetine compared to placebo during the perception of
negative versus neutral emotional pictures
Brodmann area Tal x, y, z Cluster size (mm3) t max p max
Reboxetine>placebo
Superior frontal gyrus/DLPFC R 6 19, −17, 71 1,141 12.02 0.000000
Posterior cingulate R 23 9, −22, 22 287 5.49 0.000138
Posterior cingulate L 23 −6, −25, 25 138 5.54 0.000128
Posterior insula L 13 −30, −34, 13 295 5.89 0.000074
Superior temporal gyrus L 22 −66, −4, 6 384 −8.77 0.000001
Middle temporal gyrus R 20 63, −43, −14 259 8.22 0.000003
Fusiform gyrus L 37 −51, −58, −23 555 7.95 0.000004
Inferior occipital gyrus R 18 42, −88, 1 240 10.47 0.000000
Inferior occipital gyrus L 18 −39, −97, −2 484 9.39 0.000001
Cuneus R 19 21, −95, 28 197 7.86 0.000004
Precuneus R 19 6, −76, 37 1,716 6.84 0.000018
Medial occipitotemporal gyrus/upper cerebellum R (Fig. 1d) 3, −76, −37 1,060 8.78 0.000001
Anterior thalamus/caudate head R 3, 0, 16 1,747 11.33 0.000000
Caudate head L −6, 17, 4 414 10.44 0.000000
Thalamus/pulvinar R (Fig. 1a) 12, −28, 7 2,902 7.70 0.000006
Cerebellum L −33, −76, −35 560 7.31 0.000009
Citalopram>placebo
Inferior frontal gyrus/VLPFC R (Fig. 2) 10 42, 44, −2 387 6.14 0.000026
Inferior frontal gyrus/VLPFC R 46 55, 38, 10 616 9.77 0.000000
Middle temporal gyrus R 21 63, −61, 10 1,359 7.71 0.000002
Middle occipital gyrus R 19 24, −100, 14 391 8.21 0.000001
Given are Talairach coordinates of the peak activation of the cluster and the cluster size in cubic millimeters (p<0.0005, corresponding to q<0.05
FDR-corrected, extent-threshold 135 mm3 contiguously)
L left, R right, D/VLPFC dorso-/ventrolateral prefrontal cortex
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in various brain regions during the processing of patho-
physiologically relevant emotional stimuli. The modulating
effects of the drugs were expected to be dependent on the
task-induced activation of various brain regions.
The regions identified as serotonin and noradrenaline
responsive in the current study correlate well with previous
studies localizing noradrenaline transporters (Schou et al.
2005) and serotonin transporters (Laruelle et al. 1988;
Varnas et al. 2004) using autoradiographic and positron
emission tomographic methods. However, noradrenaline
and serotonin transporters are widespread according to
these localizing studies. Therefore, the additional functional
approach increases the specificity of the results.
Previous studies examining interactions between behav-
ioral tasks and pharmacological influences on brain activity
using pharmaco-fMRI have revealed somewhat divergent
results. For example, citalopram has been shown to
increase amygdala activity in response to facial expressions
(Bigos et al. 2008) and without any stimulus (McKie et al.
2005), but it has also been shown to reduce amygdala
responses to fearful facial expressions (Murphy et al. 2009).
Frontal cortex activity has been shown to increase after
citalopram during the recognition of disgusted faces
(Anderson et al. 2007), whereas in a sustained attention
task citalopram decreased prefrontal activity (Wingen et al.
2008). Thalamic activity was reduced in the same study
(Wingen et al. 2008). However, during the recognition of
disgusted faces, citalopram increased thalamus activity
(Anderson et al. 2007). Furthermore, temporal, insular, and
occipital regions are modulated by citalopram (Anderson et
al. 2007; Wingen et al. 2008).
Acute tryptophan depletion (ATD) has been used to
reduce availability and levels of serotonin in the brain.
Studies applying ATD in healthy subjects during fMRI
revealed increased activity in frontal brain regions in
response to emotional faces (Fusar-Poli et al. 2007; Daly
et al. 2010) as well as during a Stroop task (Horacek et al.
2005), whereas two studies using Go/Nogo paradigms
showed decreased activity in frontal regions (Rubia et al.
2005; Evers et al. 2006). Cingulate activity was increased
in one study (Fusar-Poli et al. 2007) using emotional faces,
but decreased in the other (Daly et al. 2010), whereas
insular activity was modulated in the opposite direction
during emotional faces (decrease in Fusar-Poli et al. 2007,
increase in Daly et al. 2010). Occipital cortical activity was
decreased in both studies using emotional faces (Fusar-Poli
et al. 2007; Daly et al. 2010).
Studies using reboxetine with emotional and non-
emotional tasks showed rather converging results, with
reboxetine increasing brain activity in the amygdala,
thalamus, putamen, insular, frontal, cingulate, parietal, and
occipital regions (Miskowiak et al. 2007; Kukolja et al.
2008; Onur et al. 2009; Grefkes et al. 2010).
Some studies have examined chronic administration of
(es)citalopram and reboxetine over the course of 3 to 7 days
(or even longer, e.g., Arce et al. 2008; Norbury et al. 2008).
Due to the duration of treatment, these results reflect the
beginning of chronic antidepressant effects (Katz et al.
Table 2 Effects of citalopram and reboxetine in anatomically defined regions of interest (ROIs)
Anatomic region Tal CIT>PLC RBX>PLC RBX>CIT
x, y, z t/p d t/p d t/p d
Amygdala R 20, −7, −15 0.234/0.812 0.08 1.629/0.129 0.57 2.552/0.025 0.89
Amygdala L −20, −7, −15 0.270/0.791 0.08 1.452/0.172 0.09 2.672/0.019 0.76
Thalamus R 9, −14, 6 −1.562/0.141 0.46 1.556/0.146 0.69 3.769/0.002 1.38
Thalamus L −9, −14, 6 −2.518/0.025 0.65 1.945/0.076 0.93 4.216/0.001 1.49
Anterior insula R 33, 13, 4 −0.538/0.599 0.19 0.209/0.838 0.09 2.111/0.055 0.88
Anterior insula L −33, 13, 4 −1.292/0.217 0.47 1.985/0.070 0.67 3.904/0.004 1.63
Rostral anterior cingulate R 6, 29, 9 0.771/0.454 0.21 1.913/0.080 0.82 1.951/0.073 0.66
Rostral anterior cingulate L −6, 29, 9 1.033/0.319 0.32 0.226/0.825 0.08 1.713/0.110 0.56
Ventral anterior cingulate R 6, 12, 25 0.215/0.806 0.09 0.499/0.627 0.21 2.691/0.019 1.03
Ventral anterior cingulate L −6, 12, 25 0.538/0.599 0.18 0.896/0.388 0.39 1.922/0.077 0.62
DLPFC R 42, 10, 33 −0.243/0.812 0.08 2.109/0.057 0.77 3.449/0.004 1.17
DLPFC L −42, 10, 33 −1.692/0.113 0.52 1.650/0.125 0.35 2.896/0.012 1.17
Size of the cubes 1,000 mm3 , except for anterior insula and DLPFC: 3,375 mm3
R right, L left, DLPFC dorsolateral prefrontal cortex, Tal Talairach coordinates of the centers of cubic ROIs, t/p paired Student’s t test (mean beta
weights of the ROI, p<0.05 in bold, p<0.10 in italic), d Cohen’s d of the mean beta weights of the ROI [d>0.75 large effect (italic), d>1.10 very
large effect (bold), d>1.45 huge effect (bold)]
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2004) in addition to the direct regulatory effects, which are
on the intracellular level detectable after 48 h (Donnici et al.
2008), rather than the acute neuromodulatory effects
examined in our study.
The noradrenergic and serotonergic systems are involved
in different aspects of regulating cognitive-emotional func-
tions. For example, the noradrenergic system is part of the
“ascending reticular activating system” and is thus strongly
involved in regulating vigilance, alertness, and motivation. In
addition to this core involvement, the noradrenergic system
also regulates several additional psychological functions,
including sensory processing, synaptic plasticity, network
tuning, and memory (Sara 2009). The serotonergic system, in
contrast, is strongly involved in the regulation of emotional
and behavioral control processes (Cools et al. 2008; Martin-
Soelch 2010). Decreases in the serotonergic tone of
vulnerable subjects have been implicated in depression and
anxiety (Cools et al. 2008). Thus, the selective stimulation of
one particular system may modulate a particular set of
psychological functions.
While there is consistent evidence for a reduced
processing of emotionally negative stimuli due to the
influence of antidepressants (however particularly with
chronic application), the results of previous studies regard-
ing the processing of positive stimuli or the induction of a
positive bias are mixed: for example, the acute application
of citalopram reduced negative mood, but had only a non-
significant effect on positive mood in one study (Harmer et
al. 2003), whereas the recognition of positive and negative
facial expressions was increased. In another study, citalo-
pram and reboxetine increased the N250 amplitude for
happy relative to sad facial expression (Kerestes et al.
2009), however without an effect on behavior and mood.
Application of citalopram and reboxetine over 7 days
resulted in no significant changes of mood in healthy
subjects (Harmer et al. 2004) and had no effect on the
recognition of happy facial expression, but decreased the
recognition of disgusted, angry, and afraid expressions and
the emotion-potentiated startle response to negative stimuli,
thus pointing to an effect on the processing of negative
stimuli. Hence, the weaker effect of noradrenergic and
serotonergic modulation in our study is in line with the
current findings in this field.
Overall, the results of the current study are in agreement
with previous studies using acute modulation of the
noradrenergic and serotonergic system. However, our
results are the first to demonstrate that noradrenergic and
serotonergic antidepressants exhibit differential modulation
of brain activity during the perception of emotional stimuli,
particularly in subcortical regions such as the thalamus,
amygdala and caudate, and also in prefrontal regions. When
comparing our current results with our previous analysis of
the anticipation period (Brühl et al. 2010), the most
prominent difference is the weaker influence of seroto-
nergic modulation in the perceptual phase, as analyzed
here. In the previous study, citalopram pre-treatment
increased brain activity in prefrontal regions (medial
prefrontal cortex, V/DLPFC) during the anticipation of
negative and potentially negative stimuli. In the current
study, we observed an influence only on the VLPFC
activity. Noradrenergic modulation induced an extended,
more prominent increase in brain activity during the
perception period, with an overlap in the DLPFC, the
posterior cingulate, the left superior temporal gyrus, and
the thalamic area. Additionally, reboxetine modulated
visual-perceptive and higher order visual processing
areas, such as the occipital cortex and the (pre)cuneus
during the perception of negative stimuli. In the direct
comparison between reboxetine and citalopram, we
found that the medial thalamus, left extended amygdale,
and visual-perceptive and higher order visual processing
areas (occipital cortex, fusiform gyrus, and precuneus)
were modulated by reboxetine during the anticipatory
phase, whereas citalopram acted in the prefrontal and
insular regions. Here, during the perception of negative
emotional stimuli (see Online Resource 4, Table 4.1),
noradrenergic influences were dominant in the frontal,
parietal, occipital, and extended subcortical areas, includ-
ing the thalamus, caudate, and amygdala. During the
anticipation and perception of negative stimuli, we found
a more prominent influence of reboxetine on the medial
thalamus compared to citalopram in both studies.
Regarding the specific region that may indicate im-
proved individual responses to either serotonergic or
noradrenergic antidepressant drugs, we propose that
noradrenergic-based interventions should be used as first-
order treatments in depressed patients with dysfunctions in
thalamic regions during the anticipation and perception of
negative emotional stimuli because these regions were
strongly modulated by reboxetine in our current and
previous studies. On the other hand, by also considering
our previous findings during the anticipation period (Brühl
et al. 2010), serotonergic intervention would be recom-
mended in patients with prefrontal, right V/DLPFC “hyper-
activations”, particularly during the anticipation of negative
emotional stimuli in depression. In a recent study in
depressed patients, the right VLPFC was one of the brain
regions differentially modulated treated with citalopram
over 6 weeks compared to reboxetine (Wagner et al. 2010),
thus confirming the relevance of our findings. A recent
meta-analysis (Cipriani et al. 2009) indicated a lower
efficacy of reboxetine compared drugs with serotonergic
effects. However, a neurobiologically based method as, for
instance, the one proposed here could help identify
subgroups of patients responding to noradrenergic or other
compounds. In such subgroups, substances with lower
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efficacy over all patients could have higher potency and
response rates (Bschor 2010).
Regarding potential modes of action, antidepressants
may induce non-specific increases in brain activity in
regions that exhibit dysfunctionally increased activity
related to depression. Although this may appear counterin-
tuitive at first, increasing non-specific activity in a certain
region may induce noise and “override” the dysfunctional
depression-related activity via synaptic adaptations and
neural reorganization. In this case, chronic treatment with
antidepressants could eliminate the dysfunctional informa-
tion processing that may underlie the aberrant emotion
processing observed in depression. Antidepressants may
further facilitate the regional processing of functional, not
pathophysiologically biased information, thus enabling a
recalibration and rebalancing of information processing
beyond the dysfunctional “depressive” attractor. Over the
course of long-term treatment, neuroplastic changes may
consolidate therapeutic effects. Of course, further investi-
gation is required to validate this model. Particularly the
transferability of the results to emotion processing in
depressed patients has to be investigated in further studies.
The principles of our approach, however, may provide a
basis for personalized treatment based on neurobiological
findings in psychiatric disorders in the future.
One limitation of our study is the relatively low number
of subjects and scans that were analyzed. Despite this
limitation, the statistical power of our study is sufficient to
achieve significance as a result of the crossover design with
repeated measures. Furthermore, our study purposely
abstains from an explicit behavioral control. Any such
behavioral measure would have induced preparatory and
executive processes. Behavioral control procedures could
have caused distractions from the task itself and reduced
emotional involvement. Follow-up interviews with the
participants confirmed their attention during scanning.
Attention was further verified by monitoring individual
brain activation in visual areas. The intake of the
administered drugs was not verified by observation or
plasma levels, but nearly all subjects reported mild,
characteristic drug side effects prior to scanning, a result
that is consistent with a high level of compliance. In
addition, because non-compliance would lead to an
underestimation of antidepressant effects, we are confident
in the validity of our results. However, because this study
was conducted in healthy subjects, future research will be
required to demonstrate the transferability of these results to
depressed patients.
In conclusion, our data provide evidence for functionally
distinguishable effects of noradrenergic and serotonergic
antidepressants in distinct brain areas, particularly during
the processing of negative emotional stimuli. This investi-
gation may serve as a step towards future studies evaluating
whether antidepressant treatment can be improved by
selecting specific antidepressant drugs based on differential
patterns of brain activity observed in different patients.
Given our current results and previous findings, we propose
that such candidate regions may include the thalamic
region, the dysfunction of which may indicate responsive-
ness to noradrenergic stimulation, and the ventrolateral
prefrontal regions, the dysfunction of which may indicate
preferential responses to serotonergic agents.
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